We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
FLY LDN is a fitness brand that imparts sports and fitness instruction via its digital platform and its studios in central London and Fitzrovia. The company launched its video-on-demand and live-streaming fitness platform, FLY LDN Online (FLO), in September 2020. It asserts that within six months of launch, FLO scaled over 28,000 monthly views across 80+ countries with users having viewed over 2.5 million minutes of FLY LDN workouts. FLY LDN won the Men's Health 'Best Studio 2019' award and was commended at the 2018 and 2019 Tatler Gym Awards. The company has also received press coverage in publications like Women's Health, Forbes, Esquire, Elle, Vogue, GQ and Glamour. It has also partnered with brands such as DKNY and ASOS. FLY LDN aspires to become a contender in the global online fitness market that is expected to reach $59 billion by 2027. The company will use the investment to further develop additional functionality and TV apps for FLO and fund marketing campaigns to fuel growth.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £340,928
OnCare is a digital care management software that is digitising elderly care, creating a global care marketplace via the OpenTable model to care. OnCare provides care agencies with the power to plan, manage and enhance care delivery and staff communication. Their mission is to make care easier for everyone. OnCare is currently live with over 110 home-care agencies around the UK, and more than 1100 care workers. The company is planning to enter markets of Hong Kong, Canada and Israel. With the proceeds, the company will use this fund for people, office space, technology, software, hosting and marketing.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £96,040
Personalised Protein Co (PPCo) is a direct-to-consumer supplement brand that bridges the gap between technology and fitness. Leveraging on the growing UK vitamin and supplement industry, which is worth over £800m, PPCo offers expert guidance, bespoke product, clear pricing, and consumer-friendly subscription service. More than 9,000 people have signed up for the company's pre-registered launch campaign providing it 1,200 customers and 5000+ Instagram followers. With the proceeds, the company will improve its technology, automation, and aim at acquiring new customers. PPCo is raising money to invest in its product and scale its marketing efforts.
days to go: Expired investment: £192,770
Riders can enjoy indoor cycling within a boutique fitness studio. In the past 6 years, Boom Cycle have opened five sites are now seeking funds to expand their portfolio. To date, Boom Cycle has acquired over £4.1m from private investors and in 2017 spent £2.1m on developing two flagship studios. The company has experienced attendance growth of 47% YoY, as well as a 77% increase in revenue YoY.
days to go: Expired investment: £805,260
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,386,200
niix is a fitness app plugging the gap in the market for women approaching 40. Since its launch in 2018, the company has created a 4+ star rated app with more than 1800 paid subscriptions across 25 countries including the US, Canada, and Australia. It also has an online following of tens of thousands. The global fitness app market is growing fast set to be worth $2 billion by 2023 with a focus on weight loss and body aesthetics for millennial markets. niix sees a huge opportunity in this space to support women who have simply outgrown an approach that want the perfect body and be fit lifelong. With the investment, the company will scale up proven marketing channels to grow community and subscriber bases, making niix the no.1 digital fitness brand for women approaching 40+.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £153,441
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go: Expired investment: £2,160,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph